Life Telegraph
  • Home
  • Top News
  • Stock Research
  • Market Coverage
  • Earnings And Estimates
No Result
View All Result
Life Telegraph
  • Home
  • Top News
  • Stock Research
  • Market Coverage
  • Earnings And Estimates
No Result
View All Result
Life Telegraph
No Result
View All Result
Home Market

Analyst Expect Big Moves From Aravive Inc. (NASDAQ: ARAV)

January 25, 2023
in Market

BVF Partners LP recently announced the acquisition of new stake in Aravive Inc. (NASDAQ:ARAV). This fresh investment now brings its stake to 8.00% valued currently at $6.32 million.

With over 0.17 million Aravive Inc. (ARAV) shares trading Tuesday and a closing price of $1.71 on the day, the dollar volume was approximately $0.28 million. The shares have shown a positive half year performance of 98.61% and its price on 01/24/23 lost nearly -2.84%. Currently, there are 30.52M common shares owned by the public and among those 29.93M shares have been available to trade.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for ARAV have a consensus price objective of $9.80. The analysts have set the share’s price value over the next 12 months at a high of $18.00 and a low of $2.00. The average price target is 82.55% above its recent price level and an upside to the estimated low will see the stock gain 14.5% over that period. But an upside of 90.5% will see the stock hit the forecast high price target while median target price for the stock is $10.00.

Insiders at the company have transacted a total of 10 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 10 of these insider trades were purchases, accounting for 23,244,562 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.

The top 3 mutual fund holders in Aravive Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.26 million shares of the company’s stock, all valued at over $0.34 million. Vanguard Extended Market Index Fu bought 302.0 shares to see its total holdings expand to 0.17 million shares valued at over $0.22 million and representing 0.28% of the shares outstanding. Fidelity Extended Market Index Fu now owns shares totaling to 0.12% of the shares outstanding.

However, the script later moved the day high at 1.8000, down -2.84%. The company’s stock has a 5-day price change of -0.58% and 107.27% over the past three months. ARAV shares are trading 29.55% year to date (YTD), with the 12-month market performance down to -23.32% lower. It has a 12-month low price of $0.58 and touched a high of $2.40 over the same period. ARAV has an average intraday trading volume of 648.40K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 11.22%, 14.73%, and 45.65% respectively.

Institutional ownership of Aravive Inc. (NASDAQ: ARAV) shares accounts for 6.70% of the company’s 30.52M shares outstanding. Mutual fund holders own 11.94%, while other institutional holders and individual stakeholders account for 51.15% and 1.08% respectively.

It has a market capitalization of $98.77M and a beta (3y monthly) value of 2.39. The earnings-per-share (ttm) stands at -$2.35. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.04% over the week and 8.65% over the month.

Analysts forecast that Aravive Inc. (ARAV) will achieve an EPS of -$0.64 for the current quarter, -$0.39 for the next quarter and -$1.62 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.69 while analysts give the company a high EPS estimate of -$0.54. Comparatively, EPS for the current quarter was -$0.53 a year ago. Earnings per share for the fiscal year are expected to decrease by -0.80%, and 38.50% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Aravive Inc. (ARAV) as a “Strong Buy” at a consensus score of 1.70. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 0 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the ARAV, a number of firms have released research notes about the stock. ROTH Capital stated their Buy rating for the stock in a research note on June 03, 2022, with the firm’s price target at $15. BTIG Research coverage for the Aravive Inc. (ARAV) stock in a research note released on March 08, 2021 offered a Buy rating with a price target of $26. Robert W. Baird on their part issued Outperform rating on December 02, 2019.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Market

Set Your Sights On The Glimpse Group Inc. (NASDAQ: VRAR)’S Upside Potential

by Annabelle Farmer
January 26, 2023
0

The Vanguard Group, Inc. has recently announced that it has increased stake in The Glimpse Group Inc. (NASDAQ:VRAR) by 374.02%....

An Important Check-Up On Edoc Acquisition Corp. (NASDAQ: ADOC)

January 26, 2023

Growth Story Still Intact For Willdan Group Inc. (WLDN)

January 26, 2023

Is Cognition Therapeutics Inc. (NASDAQ: CGTX) Proving The Doubters Wrong?

January 26, 2023

Lifetime Brands Inc. (NASDAQ: LCUT) Stock In Prove Me State

January 26, 2023

Are Analysts Expecting A Better 2020 For Aura Biosciences Inc. (AURA)?

January 26, 2023
fav

Categories

  • Market
  • Finance
  • Industry
  • Top News
  • Stock Research
  • Market Coverage
  • Earnings And Estimates

Company

  • Home
  • About Us
  • Our Team
  • Contact Us

Recent Posts

  • Set Your Sights On The Glimpse Group Inc. (NASDAQ: VRAR)’S Upside Potential
  • An Important Check-Up On Edoc Acquisition Corp. (NASDAQ: ADOC)
  • Growth Story Still Intact For Willdan Group Inc. (WLDN)

Copyright © 2022 Life Telegraph.

No Result
View All Result
  • Home
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

Copyright © 2022 Life Telegraph.

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?